BR9607310A - Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante - Google Patents

Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante

Info

Publication number
BR9607310A
BR9607310A BR9607310A BR9607310A BR9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A BR 9607310 A BR9607310 A BR 9607310A
Authority
BR
Brazil
Prior art keywords
agent
immunisuppressive
recombinant adenovirus
combining drugs
vivo
Prior art date
Application number
BR9607310A
Other languages
English (en)
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Hedi Haddada
Michelle Webb
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of BR9607310A publication Critical patent/BR9607310A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9607310A 1995-02-14 1996-02-12 Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante BR9607310A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
BR9607310A true BR9607310A (pt) 1997-11-25

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607310A BR9607310A (pt) 1995-02-14 1996-02-12 Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante

Country Status (23)

Country Link
US (2) US20030004091A1 (pt)
EP (1) EP0809516B1 (pt)
JP (1) JPH11500430A (pt)
KR (1) KR100402540B1 (pt)
AT (1) ATE204481T1 (pt)
AU (1) AU717218B2 (pt)
BR (1) BR9607310A (pt)
CA (1) CA2211039C (pt)
CZ (1) CZ258197A3 (pt)
DE (1) DE69614668T2 (pt)
DK (1) DK0809516T3 (pt)
ES (1) ES2163612T3 (pt)
FI (1) FI119176B (pt)
FR (1) FR2730411B1 (pt)
GR (1) GR3036438T3 (pt)
HU (1) HU222991B1 (pt)
IL (1) IL117116A0 (pt)
MX (1) MX9706017A (pt)
NO (1) NO320072B1 (pt)
PT (1) PT809516E (pt)
SK (1) SK282235B6 (pt)
WO (1) WO1996025177A1 (pt)
ZA (1) ZA961161B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
CA2308017A1 (en) 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
IL152450A0 (en) 2000-05-12 2003-05-29 Genzyme Corp COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
EP1562571B1 (en) * 2002-11-21 2011-08-17 Genzyme Corporation Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 AND ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF AUTOIMMUNITY
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
MX9706017A (es) 1997-11-29
FI119176B (fi) 2008-08-29
FI973323A0 (fi) 1997-08-13
ATE204481T1 (de) 2001-09-15
KR100402540B1 (ko) 2004-05-07
FI973323A (fi) 1997-08-13
HUP9800635A2 (hu) 1998-07-28
DK0809516T3 (da) 2001-12-17
SK110897A3 (en) 1998-01-14
CA2211039C (fr) 2011-12-06
ES2163612T3 (es) 2002-02-01
GR3036438T3 (en) 2001-11-30
NO973724D0 (no) 1997-08-13
NO973724L (no) 1997-08-13
KR19980702199A (ko) 1998-07-15
EP0809516B1 (fr) 2001-08-22
NO320072B1 (no) 2005-10-17
SK282235B6 (sk) 2001-12-03
ZA961161B (en) 1996-08-07
EP0809516A1 (fr) 1997-12-03
FR2730411A1 (fr) 1996-08-14
HU222991B1 (hu) 2004-01-28
CA2211039A1 (fr) 1996-08-22
US20030004091A1 (en) 2003-01-02
DE69614668T2 (de) 2002-06-27
CZ258197A3 (en) 1997-11-12
WO1996025177A1 (fr) 1996-08-22
IL117116A0 (en) 1996-06-18
AU4723896A (en) 1996-09-04
PT809516E (pt) 2002-02-28
DE69614668D1 (de) 2001-09-27
US20040265276A1 (en) 2004-12-30
JPH11500430A (ja) 1999-01-12
FR2730411B1 (fr) 1997-03-28
HUP9800635A3 (en) 2000-12-28
AU717218B2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
BR9607310A (pt) Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
MX9706109A (es) Moleculas de adn, preparacion y utilizacion en terapia genica.
HUP9800863A3 (en) Drug delivery system for two or more active substances
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
ES2130428T3 (es) Cristales de insulina asp-b28.
AU2832297A (en) Morphogen treatment for chronic renal failure
PL317105A1 (en) Compositions containing dna and p53 damaging agents
WO1996040055A3 (en) Biological agent compositions
IL129445A0 (en) Improvements in or relating to diagnostic/therapeutic agents
EP0766974A3 (en) Blood reservoir, blood delivery instrument, and blood delivery apparatus
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
ZA992406B (en) Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy.
AU2001258638A1 (en) Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
Agrawal Antisense oligonucleotides as gene expression modulators
ITRM940545A0 (it) Preparato ad uso cosmetico e/o farmaceutico, con carbone attivo e sostanze disperdenti.
MX9803093A (es) Suministro de polipeptidos biologicamente activos.
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C
IT1298412B1 (it) Regolatore di flusso atto a controllare con precisione la quantit{ di una soluzione fisiologica e/o medicamentosa infusa in un paziente

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.